Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Athimalaipet Vaidyanathan RamananAndrew D DickAshley P JonesDyfrig A HughesAndrew J McKayAnna Rosala-HallasPaula R WilliamsonBen HardwickHelen HickeyNaomi Ea RainfordGraeme L HickeyRuwanthi Kolamunnage-DonaGiovanna CuledduCatrin O PlumptonEifiona WoodSandrine Compeyrot-LacassagnePatricia WooClive EdelstenMichael William BeresfordPublished in: Health technology assessment (Winchester, England) (2020)
This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 23, No. 15. See the NIHR Journals Library website for further project information. This trial was also funded by Arthritis Research UK (grant reference number 19612). Two strengths of adalimumab (20 mg/0.8 ml and 40 mg/0.8 ml) and a matching placebo were manufactured by AbbVie Inc. (the Marketing Authorisation holder) and supplied in bulk to the contracted distributor (Sharp Clinical Services, Crickhowell, UK) for distribution to trial centres.
Keyphrases
- juvenile idiopathic arthritis
- quality improvement
- healthcare
- phase iii
- study protocol
- public health
- mental health
- disease activity
- health information
- rheumatoid arthritis
- phase ii
- cross sectional
- randomized controlled trial
- primary care
- open label
- low dose
- health promotion
- systematic review
- meta analyses
- human health
- social media
- ankylosing spondylitis
- risk assessment